Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Annexon Inc (ANNX)

Annexon Inc (ANNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Jan 16, 4:05PM CST

BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 6.85 (+11.20%)
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 GlobeNewswire - Mon Jan 12, 6:00AM CST

Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for  Guillain-Barré Syndrome ( GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal...

ANNX : 6.85 (+11.20%)
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome GlobeNewswire - Thu Jan 8, 7:00AM CST

Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan....

ANNX : 6.85 (+11.20%)
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Wed Jan 7, 3:05PM CST

BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 6.85 (+11.20%)
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Dec 16, 2025

BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across...

ANNX : 6.85 (+11.20%)
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million GlobeNewswire - Fri Nov 14, 2025

BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across...

ANNX : 6.85 (+11.20%)
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Wed Nov 12, 2025

BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across...

ANNX : 6.85 (+11.20%)
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Wed Nov 12, 2025

BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing...

ANNX : 6.85 (+11.20%)
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones GlobeNewswire - Mon Nov 10, 2025

Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in  Guillain-Barré Syndrome ( GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA...

ANNX : 6.85 (+11.20%)
Annexon Biosciences to Participate in Upcoming September Investor Conferences GlobeNewswire - Wed Aug 27, 2025

BRISBANE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating...

ANNX : 6.85 (+11.20%)

Barchart Exclusives

How to Buy RKT for a 9% Discount, or Achieve a 45% Annual Return Barchart - 4 minutes ago
Selling cash secured puts on stocks an investor is happy to take ownership of is a great way to generate some extra income. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot